Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BVSNASDAQ:LNSRNASDAQ:RXSTNASDAQ:SIBN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$7.43-2.9%$8.95$3.90▼$14.38$608.84M0.92447,893 shs350,667 shsLNSRLENSAR$14.03+0.9%$13.62$2.95▼$17.31$165.40M0.5671,521 shs223,556 shsRXSTRxSight$14.56-2.6%$21.82$13.50▼$66.54$591.43M1.26628,509 shs859,558 shsSIBNSI-BONE$14.47+0.4%$14.93$11.70▼$19.16$614.30M1.02359,295 shs277,689 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus-2.88%-0.93%-17.72%-28.69%+86.68%LNSRLENSAR+0.86%+1.74%-0.71%+26.06%+333.02%RXSTRxSight-2.61%+2.54%-45.18%-54.29%-72.41%SIBNSI-BONE+0.42%+7.58%+3.06%-12.62%-0.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBVSBioventus3.2666 of 5 stars3.30.00.00.02.94.21.3LNSRLENSAR0.8152 of 5 stars1.03.00.00.02.82.50.0RXSTRxSight2.8689 of 5 stars4.11.00.00.03.12.50.6SIBNSI-BONE4.1702 of 5 stars3.53.00.03.33.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 2.67Moderate Buy$15.00101.88% UpsideLNSRLENSAR 2.00Hold$15.006.91% UpsideRXSTRxSight 2.20Hold$37.60158.24% UpsideSIBNSI-BONE 3.00Buy$24.4068.62% UpsideCurrent Analyst Ratings BreakdownLatest LNSR, SIBN, BVS, and RXST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2025RXSTRxSightPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$18.004/9/2025RXSTRxSightUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$45.00 ➝ $16.004/4/2025RXSTRxSightJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Underweight$40.00 ➝ $17.004/3/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$35.00 ➝ $22.004/3/2025RXSTRxSightBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$36.00 ➝ $22.004/3/2025RXSTRxSightNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$43.00 ➝ $43.003/24/2025LNSRLENSARBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/24/2025LNSRLENSARLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$16.00 ➝ $15.003/21/2025RXSTRxSightBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $36.003/19/2025RXSTRxSightStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$33.00 ➝ $28.003/17/2025BVSBioventusCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$573.28M1.06$0.59 per share12.58$2.80 per share2.65LNSRLENSAR$53.49M3.09N/AN/A$2.97 per share4.72RXSTRxSight$139.93M4.23N/AN/A$4.47 per share3.26SIBNSI-BONE$167.18M3.67N/AN/A$4.18 per share3.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus-$156.23M-$0.51N/A16.15N/A-7.11%15.61%4.01%N/ALNSRLENSAR-$14.38M-$2.72N/A∞N/A-34.03%-49.02%-21.12%5/8/2025 (Estimated)RXSTRxSight-$48.61M-$0.72N/AN/AN/A-23.92%-14.00%-12.51%5/7/2025 (Estimated)SIBNSI-BONE-$43.34M-$0.76N/AN/AN/A-23.82%-22.51%-16.53%5/5/2025 (Estimated)Latest LNSR, SIBN, BVS, and RXST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025LNSRLENSAR-$0.1550N/AN/AN/A$13.40 millionN/A5/7/2025N/ARXSTRxSight-$0.03N/AN/AN/A$38.74 millionN/A5/5/2025Q1 2025SIBNSI-BONE-$0.24N/AN/AN/A$45.13 millionN/A2/27/2025Q4 2024LNSRLENSAR-$0.21-$1.61-$1.40-$1.61$14.95 million$16.73 million2/25/2025Q4 2024RXSTRxSight$0.10-$0.15-$0.25-$0.15$40.23 million$40.21 million2/24/2025Q4 2024SIBNSI-BONE-$0.16-$0.11+$0.05-$0.11$48.87 million$49.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/ALNSRLENSARN/AN/AN/AN/AN/ARXSTRxSightN/AN/AN/AN/AN/ASIBNSI-BONEN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.851.410.99LNSRLENSARN/A3.372.10RXSTRxSightN/A12.6711.71SIBNSI-BONE0.228.257.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%LNSRLENSAR40.15%RXSTRxSight78.78%SIBNSI-BONE98.11%Insider OwnershipCompanyInsider OwnershipBVSBioventus32.90%LNSRLENSAR38.52%RXSTRxSight9.36%SIBNSI-BONE3.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20081.94 million54.46 millionNot OptionableLNSRLENSAR11011.79 million7.14 millionOptionableRXSTRxSight22040.62 million36.53 millionOptionableSIBNSI-BONE35042.45 million40.30 millionOptionableLNSR, SIBN, BVS, and RXST HeadlinesRecent News About These CompaniesRenaissance Technologies LLC Invests $1.56 Million in SI-BONE, Inc. (NASDAQ:SIBN)April 29 at 3:49 AM | marketbeat.comMarshall Wace LLP Has $3.71 Million Stock Position in SI-BONE, Inc. (NASDAQ:SIBN)April 28 at 4:11 AM | marketbeat.comSI-BONE, Inc. (NASDAQ:SIBN) Shares Sold by Russell Investments Group Ltd.April 27 at 3:26 AM | marketbeat.comJPMorgan Chase & Co. Acquires 102,660 Shares of SI-BONE, Inc. (NASDAQ:SIBN)April 22, 2025 | marketbeat.comSI-BONE, Inc. (NASDAQ:SIBN) Shares Sold by Champlain Investment Partners LLCApril 20, 2025 | marketbeat.comSI-BONE (NASDAQ:SIBN) Shares Gap Up - What's Next?April 17, 2025 | marketbeat.comSI-BONE (NASDAQ:SIBN) Shares Down 4.5% - Time to Sell?April 16, 2025 | marketbeat.comTrexquant Investment LP Invests $1.23 Million in SI-BONE, Inc. (NASDAQ:SIBN)April 13, 2025 | marketbeat.comWellington Management Group LLP Lowers Position in SI-BONE, Inc. (NASDAQ:SIBN)April 13, 2025 | marketbeat.comSI-Bone price target lowered to $20 from $22 at TruistApril 12, 2025 | markets.businessinsider.comSI-BONE’s Sales Accelerated in final 2024 QuarterApril 11, 2025 | ryortho.comSI-BONE, Inc.: Small-cap Developer Of Medical Implants And A Steady Revenue GrowerApril 8, 2025 | seekingalpha.comSI-BONE, Inc. (NASDAQ:SIBN) SVP Sells $44,229.92 in StockApril 6, 2025 | insidertrades.comSI-BONE, Inc. (NASDAQ:SIBN) SVP Michael A. Pisetsky Sells 3,128 SharesApril 6, 2025 | marketbeat.comInsider Selling: SI-BONE, Inc. (NASDAQ:SIBN) Insider Sells 3,311 Shares of StockApril 6, 2025 | marketbeat.comRaymond James Financial Inc. Buys New Shares in SI-BONE, Inc. (NASDAQ:SIBN)April 4, 2025 | marketbeat.comShort Interest in SI-BONE, Inc. (NASDAQ:SIBN) Rises By 40.5%March 31, 2025 | marketbeat.comAmerican Century Companies Inc. Raises Stock Position in SI-BONE, Inc. (NASDAQ:SIBN)March 30, 2025 | marketbeat.comHow SI-BONE, Inc. (NASDAQ:SIBN) Continues to Perform Despite Fluctuating Market SupportMarch 8, 2025 | kalkinemedia.comSI-BONE, Inc. 2024 Q4 - Results - Earnings Call PresentationMarch 4, 2025 | seekingalpha.comQ4 2024 SI-BONE Inc Earnings CallFebruary 26, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLNSR, SIBN, BVS, and RXST Company DescriptionsBioventus NYSE:BVS$7.43 -0.22 (-2.88%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$7.45 +0.02 (+0.27%) As of 04:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.LENSAR NASDAQ:LNSR$14.03 +0.12 (+0.86%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$14.02 0.00 (-0.04%) As of 04:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.RxSight NASDAQ:RXST$14.56 -0.39 (-2.61%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$14.56 -0.01 (-0.03%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.SI-BONE NASDAQ:SIBN$14.47 +0.06 (+0.42%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$14.46 -0.01 (-0.07%) As of 04:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Rebounds After Strong Earnings and Buyback Announcement Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? The Bear Market Has Only Just Started - Here's Why MarketBeat Week in Review – 04/21 - 04/25 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy Bears Can Reap Big Benefits With These 3 Short ETF Bets Why Institutions Are Buying Super Micro Computer Stock Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
